1. At a Glance – The Masala Headline Nobody Asked For but Everyone Needs
Bajaj Healthcare Ltd is that one pharma company which looks harmless on the outside but hides enough balance-sheet drama to make a daily soap writer blush. Current market cap stands at ₹1,236 crore, the stock is chilling at ₹391, down ~30% over one year, and investors are still asking the same existential question: “Yeh company revival mode mein hai ya sirf Excel formatting achhi ho gayi?”
Q3 FY26 numbers look deceptively decent. Quarterly sales came in at ₹161 crore, up 31% YoY, while PAT stood at ₹16 crore, translating into an EPS of ₹4.96 for the quarter. Annualise that (because yes, these are Quarterly Results and we lock that in right here), and you’re staring at an annualised EPS of roughly ₹19.8. Against a CMP of ₹391, the recalculated P/E lands close to ~19.7x, lower than the stated trailing multiple of 23.6x.
Debt has reduced to ₹238 crore from a scary ₹415 crore two years ago, ROCE is a modest 11.4%, ROE is 10.7%, and margins hover around 15%. On paper, this looks like a company that finally attended its financial physiotherapy sessions. In reality, working capital days have exploded to 140, debtor days are at 169, and inventory days are north of 200.
So yes, the patient is alive. But the ICU bill is still pending. Curious? You should be.
2. Introduction – Welcome to the Pharma Crime Scene
Bajaj Healthcare is not new to the Indian pharma ecosystem. Incorporated in 1993, this company has seen liberalisation, price controls, API cycles, China disruptions, COVID sugar highs, and post-COVID hangovers. And like a seasoned Mumbai local, it has survived everything—barely.
The company plays in APIs, intermediates, and finished dosage formulations, exporting to over 62 countries and supplying to more than 550 clients. Sounds impressive until you realise that pharma exports are like Indian weddings—big guest list, but cash flow depends on who actually pays on time.
FY24 was ugly. FY25 showed a turnaround. FY26 so far is… confusing but hopeful. The company reported a full-year loss in FY24, followed by a recovery in FY25 with PAT of ₹40 crore, and now Q3 FY26 has delivered ₹16 crore PAT in a single quarter. That’s not nothing.
But this is also a company that once reported negative EPS of ₹-30.36 in FY24, had massive other income shocks, and watched its promoter holding fall from ~67% to ~59%. So before you celebrate, remember: Bajaj Healthcare has a PhD in volatility.
Question for you: Is this a turnaround story or just a quarterly sugar rush?
3. Business Model – WTF Do They Even Do?
Bajaj Healthcare does three broad things, and does them at industrial scale:
- Intermediates – These are chemical building blocks used internally and sold externally. Think of them as the masalas before the biryani.
- Active Pharmaceutical Ingredients (APIs) – The actual drugs that make medicines work. This is where the money should be.
- Finished Dosage Formulations (FDFs) – Tablets, capsules, powders. Basically, the final “ready to swallow” products.
The company operates 9 manufacturing units across Maharashtra and Gujarat, with combined API capacity of ~730 MT per month and formulations capacity of ~92 million pieces per month. It is also:
- The world’s largest manufacturer of Chlorhexidine Base
- India’s largest manufacturer of Ascorbic Acid
Yes, Vitamin C is literally paying Bajaj Healthcare’s electricity bills.
Exports account for ~66%
